CytoDyn Capital Expenditures (CapEx) Growth & History (CYDY)
CytoDyn's capital expenditures (capex) was $122,000 for fiscal 2021.
View full CytoDyn company overviewCytoDyn annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2021 | 2021-05-31 | $122,000 | $81,000 | +197.56% |
| 2020 | 2020-05-31 | $41,000 | $15,000 | +57.69% |
| 2019 | 2019-05-31 | $26,000 | $26,000 | — |
| 2018 | 2018-05-31 | $0 | −$11,114 | — |
| 2017 | 2017-05-31 | $11,114 | −$835 | −6.99% |
| 2016 | 2016-05-31 | $11,949 | −$6,636 | −35.71% |
| 2015 | 2015-05-31 | $18,585 | −$635 | −3.30% |
| 2014 | 2014-05-31 | $19,220 | $16,085 | +513.08% |
| 2013 | 2013-05-31 | $3,135 | — | — |
| 2011 | 2011-05-31 | $4,705 | — | — |
CytoDyn quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q3 2022 | 2022-02-28 | $17,000 | −$6,000 | −26.09% |
| Q2 2022 | 2021-11-30 | $5,000 | −$13,000 | −72.22% |
| Q1 2022 | 2021-08-31 | $8,000 | −$51,000 | −86.44% |
| Q4 2021 | 2021-05-31 | $22,000 | $19,000 | +633.33% |
| Q3 2021 | 2021-02-28 | $23,000 | −$1,000 | −4.17% |
| Q2 2021 | 2020-11-30 | $18,000 | $9,000 | +100.00% |
| Q1 2021 | 2020-08-31 | $59,000 | $54,000 | +1080.00% |
| Q4 2020 | 2020-05-31 | $3,000 | −$19,818 | −86.85% |
| Q3 2020 | 2020-02-29 | $24,000 | $23,080 | +2508.70% |
| Q2 2020 | 2019-11-30 | $9,000 | $9,000 | — |
| Q1 2020 | 2019-08-31 | $5,000 | $2,738 | +121.04% |
| Q4 2019 | 2019-05-31 | $22,818 | — | — |
| Q3 2019 | 2019-02-28 | $920 | — | — |
| Q2 2019 | 2018-11-30 | $0 | — | — |
| Q1 2019 | 2018-08-31 | $2,262 | — | — |
| Q4 2017 | 2017-05-31 | $3,210 | — | — |
| Q3 2017 | 2017-02-28 | $4,424 | — | — |
| Q2 2017 | 2016-11-30 | $0 | — | — |
| Q1 2017 | 2016-08-31 | $3,480 | — | — |
| Q4 2015 | 2015-05-31 | $2,532 | −$3.5M | −99.93% |
| Q3 2015 | 2015-02-28 | $1 | $1 | — |
| Q2 2015 | 2014-11-30 | $891 | −$7,979 | −89.95% |
| Q1 2015 | 2014-08-31 | $16,943 | $14,596 | +621.90% |
| Q4 2014 | 2014-05-31 | $3.5M | $3.5M | — |
| Q3 2014 | 2014-02-28 | $0 | −$2,038 | — |
| Q2 2014 | 2013-11-30 | $8,870 | $8,064 | +1000.50% |
| Q1 2014 | 2013-08-31 | $2,347 | $2,056 | +706.53% |
| Q4 2013 | 2013-05-31 | $0 | — | — |
| Q3 2013 | 2013-02-28 | $2,038 | — | — |
| Q2 2013 | 2012-11-30 | $806 | — | — |
| Q1 2013 | 2012-08-31 | $291 | — | — |
| Q4 2011 | 2011-05-31 | $1 | — | — |
| Q3 2011 | 2011-02-28 | $1 | — | — |
| Q2 2011 | 2010-11-30 | $1,225 | — | — |
| Q1 2011 | 2010-08-31 | $3,480 | — | — |
CytoDyn capital expenditures (capex) trends
Over the last five fiscal years, CytoDyn's capital expenditures (capex) increased from $11,949 to $122,000, a change of $110,051. The latest reported quarter, Q3 2022, shows $17,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CytoDyn source filings ↗